[Betta Pharmaceuticals: Partner DURAVYU’s phase III clinical trial for the treatment of wAMD failed to meet the primary endpoint The company will conduct impairment testing on voronib-related asset groups] On October 19th, Betta Pharmaceuticals (300558.SZ) announced that the company's partner EyePoint announced the second key phase III clinical trial LUCIA data of DURAVYU in the treatment of wet age-related macular degeneration ("wAMD"). The study did not meet the preset primary endpoint and failed to prove statistical non-inferiority compared to the aflibercept 2mg control group. Key secondary endpoints were achieved. The company will conduct impairment testing on Voronib-related asset groups, which may have a certain impact on the net profit of the current period. This product is still in the clinical trial stage and has not yet been commercialized. The clinical results will not have a significant impact on current production and operations.